Thus, the findings of this study indicated that the interaction between TCF4 and TWIST1 is a potential molecular therapeutic target for lung cancer-induced cachexia and that emodin and emodin-enriched Pc-Ex, which inhibit TCF4–TWIST1 interaction, are promising therapeutic candidates for lung cancer-induced cachexia. This evidence concerns the gene TCF4 and lung carcinoma.